LinkGevity
CompanyUnited Kingdom
LinkGevity develops 4 assets, the furthest preclinical (LINK-001 in ageing). Mostly small molecule; based in the United Kingdom.
- 4
- Assets
- Furthest stage
- Preclinical
- Raised
- £1.6m
- 0
- Trials
- 2
- Signals
Pipeline
4Inhibits necrosis.
Preclinical, Small molecule, ageing, kidney disease
Inhibits necrosis to extend cell viability and enable tissue engineering.
Preclinical, lab reagent market, tissue engineering
Inhibits necrosis to extend organ preservation windows.
Preclinical, organ preservation
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants8
- People12
- Signals5
- Similar companies6